Editor’s note: This article has been updated following the 12 September Health Ministers’ Meeting in Perth. Ministers discussed regulatory challenges in the cosmetic injectables sector, including inconsistent regulation, cross-border and telehealth workarounds, and non-compliant practices. Jump to the update →
Queensland Health Minister Tim Nicholls is pushing for national reforms to the cosmetic injectables industry, calling for consistent laws across Australia to protect patient safety. The move follows regulatory clarifications in Queensland that have disrupted the common business model for nurse-led clinics.
The situation in Queensland
Queensland Health first released a fact sheet on cosmetic injectables in December 2024, outlining how the Medicines and Poisons Act 2019 applied to Schedule 4 medicines. However, confusion quickly spread across the sector about what the guidance meant in practice.
In April 2025, Queensland Health issued a further clarification of the fact sheet, making explicit that only a prescriber – a doctor or nurse practitioner – can hold and control Schedule 4 medicines on-site.
Until then, many nurse-led cosmetic clinics had operated under a model where a telehealth doctor provided a remote prescription, enabling nurses to store and administer prescription-only injectables such as Botox and dermal fillers. The April clarification effectively ended this practice.
For nurse-led clinics to continue operating, patients must now obtain a prescription and have the medication dispensed off-site before returning for treatment, adding a layer of cost and complexity to the process.
Concerns over the new regulations
The clarification has triggered alarm and opposition within the industry, particularly among cosmetic nurses who believed their business models were compliant until now.
-
Business disruption: Many nurse-led clinics fear the new rules make their operations financially unviable, with some already pausing services.
-
Cost pressures: Hiring on-site doctors or adding dispensing steps is expected to increase patient costs.
-
Safety risks: Nurses warn the changes may drive patients to bypass clinics altogether – either by sourcing injectables online or through pharmacies – and attempt to self-inject.
In June, nurses staged a protest outside Queensland Parliament, warning that the changes disproportionately affect female health professionals and could push the industry underground.
The push for national reform
Amid growing industry backlash, Health Minister Tim Nicholls has warned that inconsistencies between state and territory rules have created opportunities for operators to structure their businesses under the least restrictive models and expand nationally, in ways that he says undermine compliant providers.
Nicholls has placed cosmetic injectables reform on the agenda for the Health Ministers’ Meeting in Perth on 12 September, setting the stage for a broader discussion.
‘I’m concerned that while telehealth provides legitimate support to in-person care in primary health care, within the cosmetic injectables industry, there are rogue operators who have no clinical accountability that could have potentially devastating results for patients,’ he said, as reported by Medical Republic.
‘I have put the consideration of the work required to improve governance, oversight and regulatory frameworks for the cosmetic injectables industry on the agenda for Health Ministers to discuss.’
Nicholls’ push comes just as the Australian Health Practitioner Regulation Agency’s (Ahpra) new guidelines for non-surgical cosmetic procedures took effect on 2 September 2025. Those reforms impose stricter requirements around practitioner training, advertising practices and the treatment of under-18s, but they do not address the central issue driving Queensland’s crackdown – the purchase, storage and custody of Schedule 4 medicines, which remains regulated at the state and territory level.
What’s next
For Queensland clinics, the immediate future remains uncertain. The regulatory shift has left many nurse-led clinics reassessing their compliance pathways, with some operators pausing treatments while seeking legal and professional guidance.
As health ministers gather in Perth, the key question is whether Queensland’s hard-line stance on injectables will set the standard nationwide – a prospect that leaves many nurse-led clinics apprehensive about the future.
Update: National Health Ministers’ Meeting, 12 September 2025
At the Health Ministers’ Meeting (HHM) in Perth on 12 September, ministers discussed the regulatory challenges in the cosmetic injectables sector. These included inconsistent regulation between jurisdictions, the use of cross-border and telehealth workarounds, and the emergence of non-compliant practices.
In the HHM communiqué, ministers also noted the new “Ahpra guidelines on safe, ethical non-surgical cosmetic practice and nurse prescribing”, which came into effect on 2 September.
According to the communiqué, the Department of Health, Disability and Ageing, together with the TGA, will continue reviewing single-product telehealth prescribing and report back to ministers in December 2025 on “any further nationally coordinated actions that may be required to ensure a patient-safety-focused regulatory environment”.
For clinics, the communiqué provides acknowledgement of sector concerns but no immediate change. The next stage will depend on the December review, leaving many practices watching closely to see if Queensland’s stricter interpretation influences future national action.
